[go: up one dir, main page]

EA201001865A1 - Противовоспалительные агенты - Google Patents

Противовоспалительные агенты

Info

Publication number
EA201001865A1
EA201001865A1 EA201001865A EA201001865A EA201001865A1 EA 201001865 A1 EA201001865 A1 EA 201001865A1 EA 201001865 A EA201001865 A EA 201001865A EA 201001865 A EA201001865 A EA 201001865A EA 201001865 A1 EA201001865 A1 EA 201001865A1
Authority
EA
Eurasian Patent Office
Prior art keywords
relates
inflammatory conditions
prevention
treating
methods
Prior art date
Application number
EA201001865A
Other languages
English (en)
Other versions
EA023302B9 (ru
EA023302B1 (ru
Inventor
Йозеф Мария Хендрик Ратс
Ренато Герард Силвано Хириви
Original Assignee
Модиквест Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Модиквест Б.В. filed Critical Модиквест Б.В.
Publication of EA201001865A1 publication Critical patent/EA201001865A1/ru
Publication of EA023302B1 publication Critical patent/EA023302B1/ru
Publication of EA023302B9 publication Critical patent/EA023302B9/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rehabilitation Therapy (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Данное изобретение относится к области лечения или предотвращения воспаления у человека и животных и относится к фармацевтическим композициям и способам лечения или предотвращения различных воспалительных состояний. Конкретно, изобретение относится к композициям и способам для лечения или предотвращения воспалительных состояний, таких как связанные с цитруллином воспалительные заболевания. Изобретение предоставляет специфичные связывающие молекулы, направленные против содержащих цитруллин эпитопов, для применения в терапии и для предотвращении воспалительных состояний.
EA201001865A 2008-06-04 2009-06-04 Способ предотвращения или лечения артрита и применение антитела, специфически реактивного к цитруллинированному эпитопу в этом способе EA023302B9 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP08157547 2008-06-04
EP08171920 2008-12-17
EP09155484 2009-03-18
PCT/EP2009/056862 WO2009147201A2 (en) 2008-06-04 2009-06-04 Anti-inflammatory agents

Publications (3)

Publication Number Publication Date
EA201001865A1 true EA201001865A1 (ru) 2011-06-30
EA023302B1 EA023302B1 (ru) 2016-05-31
EA023302B9 EA023302B9 (ru) 2016-10-31

Family

ID=40943595

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001865A EA023302B9 (ru) 2008-06-04 2009-06-04 Способ предотвращения или лечения артрита и применение антитела, специфически реактивного к цитруллинированному эпитопу в этом способе

Country Status (16)

Country Link
US (2) US9718877B2 (ru)
EP (1) EP2294086B1 (ru)
JP (1) JP5528436B2 (ru)
KR (1) KR101752499B1 (ru)
CN (1) CN102056944A (ru)
AU (1) AU2009253923B2 (ru)
BR (1) BRPI0913945A2 (ru)
CA (1) CA2726511C (ru)
DK (1) DK2294086T3 (ru)
EA (1) EA023302B9 (ru)
ES (1) ES2652127T3 (ru)
IL (1) IL209741A0 (ru)
NO (1) NO2294086T3 (ru)
PL (1) PL2294086T3 (ru)
WO (1) WO2009147201A2 (ru)
ZA (1) ZA201008727B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102056944A (zh) 2008-06-04 2011-05-11 莫蒂克斯特私人有限公司 抗炎症药剂
EP2332987A1 (en) 2009-12-10 2011-06-15 ModiQuest B.V. Anti-inflammatory agents directed against citrullinated epitopes
US20110262505A1 (en) 2010-04-22 2011-10-27 Gina Athwal Seaweed-derived cosmetic compositions
EP2402368A1 (en) * 2010-07-02 2012-01-04 Toscana Biomarkers S.r.l. Histone citrullinated peptides and uses thereof
EP2527841A1 (en) * 2011-05-25 2012-11-28 Toscana Biomarkers S.r.l. Methods for the diagnosis of rheumatoid arthritis
KR101458100B1 (ko) 2012-01-13 2014-11-05 가톨릭대학교 산학협력단 류마티스 관절염 진단 키트
WO2013105721A1 (ko) * 2012-01-13 2013-07-18 가톨릭대학교 산학협력단 류마티스 관절염 진단 키트
EP2804876A4 (en) * 2012-01-19 2016-02-24 Vilara Ab NEW ANTIBODIES
FR3007411B1 (fr) * 2013-06-21 2015-07-03 Agronomique Inst Nat Rech Anticorps monocatenaire a chaine lourde de camelide dirige contre la chromatine et utilisations
EP3024849A2 (en) * 2013-07-24 2016-06-01 Vilara AB Novel antibodies for the diagnosis and treatment of rheumatoid arthritis
WO2015169602A1 (en) * 2014-05-05 2015-11-12 Noviosmart Method for the serological diagnosis of rheumatoid arthritis.
CA2969635C (en) 2014-12-11 2022-09-13 Modiquest B.V. Method for the treatment of idiopathic pulmonary fibrosis
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
CA2984380A1 (en) * 2015-05-05 2016-11-10 The Regents Of The University Of California H3.3 ctl peptides and uses thereof
US11866512B2 (en) 2017-11-22 2024-01-09 Vacara Ab Antibodies to citrullinated proteins
CU24508B1 (es) * 2017-12-29 2021-04-07 Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma Composición farmacéutica que comprende péptido tipo apl
CA3102360A1 (en) * 2018-06-20 2019-12-26 Pharma Foods International Co., Ltd. Novel anti-pad2 antibody
WO2020038963A1 (en) 2018-08-21 2020-02-27 Modiquest B.V. Antibodies binding to citrullinated histone 2a and/or 4
WO2022233931A1 (en) 2021-05-04 2022-11-10 Citryll B.V. Inhibition of eosinophilic traps
EP4085973A1 (en) 2021-05-04 2022-11-09 Citryll B.V. Inhibition of eosinophil extracellular traps
EP4442705A1 (en) 2023-04-03 2024-10-09 Citryll B.V. Dosage

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
NL1004539C2 (nl) 1996-11-15 1998-05-20 Stichting Tech Wetenschapp Peptide afgeleid van een door auto-antilichamen van patiënten met reumatoïde artritis herkend antigeen, antilichaam daartegen en werkwijze voor het detecteren van auto-immuunantilichamen.
EP1034186A2 (en) * 1997-11-28 2000-09-13 Innogenetics N.V. Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment
WO2001046222A2 (en) 1999-12-21 2001-06-28 Innogenetics N.V. Peptides designed for the diagnosis and treatment of rheumatoid arthritis
JP2007524583A (ja) 2003-03-07 2007-08-30 ロンドン・ヘルス・サイエンシズ・センター・リサーチ・インコーポレーテッド 自己免疫異常に関わるｈｌａ−ｄｒｍｈｃクラスｉｉ分子に関するペプチド
GB0721605D0 (en) 2007-11-02 2007-12-12 Cancer Rec Tech Ltd Prostrate cancer susceptibility screening
CN102056944A (zh) 2008-06-04 2011-05-11 莫蒂克斯特私人有限公司 抗炎症药剂

Also Published As

Publication number Publication date
WO2009147201A2 (en) 2009-12-10
DK2294086T3 (en) 2018-01-02
US20110243945A1 (en) 2011-10-06
KR101752499B1 (ko) 2017-06-29
JP2011523555A (ja) 2011-08-18
ZA201008727B (en) 2012-01-25
CA2726511C (en) 2018-07-10
US9718877B2 (en) 2017-08-01
KR20110015035A (ko) 2011-02-14
CA2726511A1 (en) 2009-12-10
US10703822B2 (en) 2020-07-07
EA023302B9 (ru) 2016-10-31
NO2294086T3 (ru) 2018-02-10
CN102056944A (zh) 2011-05-11
WO2009147201A3 (en) 2010-01-28
BRPI0913945A2 (pt) 2016-09-27
AU2009253923B2 (en) 2014-02-13
ES2652127T3 (es) 2018-01-31
EP2294086A2 (en) 2011-03-16
JP5528436B2 (ja) 2014-06-25
IL209741A0 (en) 2011-02-28
US20170298146A1 (en) 2017-10-19
EP2294086B1 (en) 2017-09-13
AU2009253923A1 (en) 2009-12-10
EA023302B1 (ru) 2016-05-31
PL2294086T3 (pl) 2018-02-28

Similar Documents

Publication Publication Date Title
EA201001865A1 (ru) Противовоспалительные агенты
EA200870254A1 (ru) Способ лечения воспалительных заболеваний
UA107783C2 (en) Isoindoline compounds for use in treating cancer
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
MX373187B (es) Terapia de combinación para tratar cáncer.
EA201370208A1 (ru) Формы рифаксимина и их применение
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
EA201290919A1 (ru) Индазольные соединения и их применение
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201170521A1 (ru) Новые соединения
EA201300171A1 (ru) Способы и композиции для терапии рака печени
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
EA201170349A1 (ru) Модуляторы mif
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
UA105290C2 (ru) АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ β-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ
EA201100505A1 (ru) Органические соединения для применения для лечения бактериальных инфекций
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
ECSP12011962A (es) Tratamientos para trastornos gastrointestinales
ECSP066986A (es) Beta-carbolinas utiles para tratar enfermedades inflamatorias
EA201101686A1 (ru) Новые композиции для лечения шмт и связанных с ней расстройств

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

PD4A Registration of transfer of a eurasian patent in accordance with the succession in title